Core Insights - Nvidia Corporation (NASDAQ: NVDA) is set to release its Q2 earnings on August 27th, prompting a review of notable statistics from the past three years of quarterly reports to assess performance trends and potential future outcomes [1]. Group 1 - The article emphasizes the importance of understanding historical quarterly performance to gauge Nvidia's future prospects [1]. - It highlights that valuation is more indicative of long-term opportunities or risks rather than short- to mid-term timing indicators [1]. - The analysis aims to provide insights based on data and written content rather than relying solely on rating systems, which may not account for different investment strategies or time horizons [1].

Core Insights - International Money Express (IMXI) reported a revenue of $161.13 million for the quarter ended June 2025, reflecting a year-over-year decline of 6.1% [1] - The earnings per share (EPS) for the same period was $0.51, down from $0.55 a year ago, with an EPS surprise of +4.08% compared to the consensus estimate of $0.49 [1] - The reported revenue was a surprise of -1.09% against the Zacks Consensus Estimate of $162.9 million [1] Revenue Breakdown - Other income was reported at $4.48 million, exceeding the average estimate of $2.1 million by two analysts, representing a year-over-year increase of +54.9% [4] - Foreign exchange gain, net, was $23.68 million, slightly below the average estimate of $23.7 million, with a year-over-year change of +3.9% [4] - Revenue from wire transfer and money order fees, net, was $132.97 million, lower than the estimated $137.03 million, indicating a year-over-year decline of -8.8% [4] Stock Performance - Shares of International Money Express have decreased by -9.9% over the past month, contrasting with the Zacks S&P 500 composite's increase of +2.7% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Financial Performance - For the quarter ended June 2025, American Public Education (APEI) reported revenue of $162.77 million, reflecting a 6.5% increase year-over-year [1] - The earnings per share (EPS) was reported at -$0.02, a decline from $0.01 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $161.01 million by 1.09% [1] - The EPS surprise was +71.43%, compared to the consensus estimate of -$0.07 [1] Key Metrics - Total student enrollment at Rasmussen University (RU) was 14,600, slightly below the average estimate of 14,700 [4] - Total student enrollment for Hondros College, Nursing Programs (HCN) was 3,700, in line with the average estimate of 3,701 [4] - Net course registrations reached 96,400, surpassing the average estimate of 94,122 [4] Revenue Breakdown - Revenue for Rasmussen University (RU) was $59.52 million, exceeding the average estimate of $56.75 million, representing a year-over-year increase of 12.2% [4] - Revenue for Hondros College, Nursing Programs (HCN) was $18.13 million, slightly below the average estimate of $18.21 million, with a year-over-year change of 10.5% [4] - Revenue for American Military & Public University (APUS) was $81.73 million, above the average estimate of $80.28 million, indicating a year-over-year increase of 6.1% [4] Stock Performance - Shares of American Public Education have returned +1.8% over the past month, outperforming the Zacks S&P 500 composite's +0.5% change [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential for outperformance in the near term [3]

CHONGQING, CHINA - JULY 29: In this photo illustration, a person holds a smartphone displaying the logo of Chevron Corporation (NYSE: CVX), an American multinational energy corporation, with the company's red and blue chevron logo visible in the background, on July 29, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)Getty ImagesChevron Corporation (NYSE: CVX) is set to announce its Q2 results on Friday, August 1, with analysts forecasting EPS of $2.15 on $48.39 billion in revenue. Th ...

Core Financial Performance - First Commonwealth Financial (FCF) reported revenue of $130.99 million for the quarter ended June 2025, marking a year-over-year increase of 9% [1] - The earnings per share (EPS) for the same period was $0.38, compared to $0.36 a year ago, indicating a positive growth trend [1] - The reported revenue exceeded the Zacks Consensus Estimate of $124.65 million by 5.09% [1] - The EPS also surpassed the consensus estimate of $0.34 by 11.76% [1] Key Metrics Analysis - The Core Efficiency Ratio was reported at 54.1%, better than the average estimate of 58.7% based on two analysts [4] - The Net Interest Margin (FTE) stood at 3.8%, slightly above the average estimate of 3.7% [4] - Total Interest-Earning Assets (FTE) amounted to $11.16 billion, exceeding the average estimate of $11.08 billion [4] - Gain on sale of mortgage loans was $1.84 million, surpassing the average estimate of $1.75 million [4] - Total Non-Interest Income reached $24.75 million, compared to the average estimate of $23 million [4] Stock Performance - Shares of First Commonwealth Financial have returned +0.5% over the past month, while the Zacks S&P 500 composite increased by +3.6% [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential for outperformance in the near term [3]

Core Insights - FactSet Research reported revenue of $585.52 million for the quarter ended May 2025, marking a year-over-year increase of 5.9% [1] - The earnings per share (EPS) for the same period was $4.27, slightly down from $4.37 a year ago, with an EPS surprise of -0.93% compared to the consensus estimate of $4.31 [1] Financial Performance Metrics - Total Annual Subscription Value (ASV) reached $2.34 billion, exceeding the average estimate of $2.32 billion [4] - The total number of clients increased to 8,811, surpassing the estimated 8,718 [4] - Total users were reported at 220,496, slightly below the average estimate of 225,123 [4] - ASV from buy-side clients remained stable at 82.3%, matching the average estimate [4] - Domestic ASV was reported at $1.51 billion, slightly above the estimated $1.50 billion [4] - International ASV was $822 million, marginally below the estimate of $824.51 million [4] - Organic ASV was $2.30 billion, just under the average estimate of $2.31 billion [4] Revenue Breakdown - Revenues from U.S. clients were $380.5 million, exceeding the average estimate of $376.58 million, reflecting a year-over-year increase of 6.7% [4] - Revenues from international clients totaled $205 million, slightly above the estimate of $204.15 million, with a year-over-year change of 4.5% [4] - Revenues from Asia Pacific clients were reported at $59.30 million, above the average estimate of $58.64 million, representing a year-over-year increase of 7.8% [4] - Revenues from EMEA clients reached $145.70 million, marginally exceeding the estimate of $145.59 million, with a year-over-year change of 3.2% [4] Stock Performance - FactSet shares have returned -8.7% over the past month, contrasting with the Zacks S&P 500 composite's +0.5% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Marriott International reported $6.26 billion in revenue for Q1 2025, a year-over-year increase of 4.8% [1] - The EPS for the same period was $2.32, compared to $2.13 a year ago, with a surprise of +2.20% against the consensus estimate of $2.27 [1] Financial Performance Metrics - Revenue from owned/leased rooms was 14,312, slightly above the average estimate of 14,214 [4] - Managed rooms totaled 567,896, below the estimated 587,915 [4] - Franchised rooms reached 1,120,634, exceeding the estimate of 1,102,261 [4] - REVPAR growth rate was 4.1%, surpassing the average estimate of 2.7% [4] - Gross fee revenues were $1.28 billion, above the estimate of $1.25 billion, reflecting a +5.4% change year-over-year [4] - Net fee revenues were $1.25 billion, compared to the average estimate of $1.23 billion, marking a +5.1% year-over-year change [4] - Franchise fees amounted to $746 million, exceeding the estimate of $727.37 million, with an +8.4% year-over-year change [4] - Base management fees were $325 million, slightly above the average estimate of $319.23 million, representing a +3.8% change year-over-year [4] Stock Performance - Marriott shares returned +15.9% over the past month, outperforming the Zacks S&P 500 composite's +11.5% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market [3]

Core Insights - Sleep Number reported a revenue of $393.26 million for the quarter ended March 2025, reflecting a decline of 16.4% year-over-year [1] - The company's EPS was -$0.38, a significant drop from $0.03 in the same quarter last year, with an EPS surprise of -245.45% against the consensus estimate of -$0.11 [1] - The revenue exceeded the Zacks Consensus Estimate of $391.57 million by 0.43% [1] Financial Performance - The total sales change rate for Sleep Number was -16%, which was worse than the estimated -14.7% by analysts [4] - The number of stores at the end of the period was 637, slightly below the average estimate of 641 [4] - The number of stores at the beginning of the period remained stable at 640, matching the average estimate [4] Market Performance - Over the past month, Sleep Number's shares have returned +10.6%, outperforming the Zacks S&P 500 composite, which saw a change of -0.2% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Boston Scientific reported revenue of $4.66 billion for the quarter ended March 2025, reflecting a year-over-year increase of 20.9% and surpassing the Zacks Consensus Estimate of $4.56 billion by 2.31% [1] - The company's EPS for the quarter was $0.75, an increase from $0.56 in the same quarter last year, exceeding the consensus EPS estimate of $0.67 by 11.94% [1] Financial Performance - Geographic Revenue from the U.S. was $2.96 billion, exceeding the average estimate of $2.86 billion and showing a year-over-year growth of 31.1% [4] - Revenue from the Rest of the World was reported at $1.70 billion, matching the average estimate from analysts [4] - Net Sales in Cardiovascular- Worldwide reached $3.09 billion, surpassing the average estimate of $2.96 billion and representing a 26.2% year-over-year increase [4] - Net Sales in MedSurg- Worldwide totaled $1.58 billion, slightly below the average estimate of $1.59 billion, but still reflecting an 11.7% increase compared to the previous year [4] Segment Performance - Cardiovascular- Cardiology- Worldwide sales were $2.43 billion, exceeding the estimated $2.31 billion and showing a 29.8% year-over-year growth [4] - MedSurg- Neuromodulation- Worldwide reported sales of $271 million, above the average estimate of $266.87 million, with a year-over-year increase of 5.9% [4] - Cardiovascular- Peripheral Interventions- Worldwide sales were $656 million, slightly below the average estimate of $658.51 million, but still reflecting a 14.5% year-over-year increase [4] Stock Performance - Over the past month, Boston Scientific shares have returned -7.8%, compared to a -6.6% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]